STAT Plus: Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported
RUBY WALLAU FOR STAT
Scientists have long known that mutations in a protein called KRAS cause cancer, but discovering drugs capable of blocking KRAS has proven difficult.
.png)
No hay comentarios:
Publicar un comentario